Solubility Temperature Dependence Predicted from 2D Structure
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Solid Solution Compositions and Use in Chronic Inflammation
(19) *EP003578172A1* (11) EP 3 578 172 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.12.2019 Bulletin 2019/50 A61K 9/14 (2006.01) A61K 47/14 (2017.01) A61K 47/44 (2017.01) A61K 31/12 (2006.01) (2006.01) (2006.01) (21) Application number: 19188174.7 A61K 31/137 A61K 31/167 A61K 31/192 (2006.01) A61K 31/216 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.01.2014 A61K 31/357 A61K 31/366 A61K 31/4178 (2006.01) A61K 31/4184 (2006.01) A61K 31/522 (2006.01) A61K 31/616 (2006.01) A61K 31/196 (2006.01) (84) Designated Contracting States: • BREW, John AL AT BE BG CH CY CZ DE DK EE ES FI FR GB London, Greater London EC2Y 8AD (GB) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • REILEY, Richard Robert PL PT RO RS SE SI SK SM TR London, Greater London EC2Y 8AD (GB) • CAPARRÓS-WANDERLEY, Wilson (30) Priority: 14.01.2013 US 201361752356 P London, Greater London EC2Y 8AD (GB) 04.02.2013 US 201361752309 P (74) Representative: Clements, Andrew Russell Niel et (62) Document number(s) of the earlier application(s) in al accordance with Art. 76 EPC: Schlich 14702460.8 / 2 925 367 9 St Catherine’s Road Littlehampton, West Sussex BN17 5HS (GB) (71) Applicant: InFirst Healthcare Limited London EC2Y 8AD (GB) Remarks: This application was filed on 24-07-2019 as a (72) Inventors: divisional application to the application mentioned • BANNISTER, Robin Mark under INID code 62. -
The Organic Chemistry of Drug Synthesis
The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date. -
United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat. -
These Two Workbooks Are Provided by As a Convenient Introduc
These two workbooks are provided by www.hansen-solubility.com as a convenient introduc They are Copyright © 2013 Prof Steven Abbott If you find bugs/issues or would like extra functionality, please email Steven Abbott [email protected] ction to some of the basic HSP methods HSP Sphere dD dP dH R Good 11 18.4 9.7 8.0 7.1 Bad 11 Test Value 16 7 8 Total 22 Delta 2.4 11.4 10.4 Distance 5.5 RED 0.77 Solvents dD dP dH MVol Score Distance Acetone 15.5 10.4 7 73.8 1 5.915773 Acetonitrile 15.3 18 6.1 52.9 0 10.52754 n-Amyl Acetate 15.8 3.3 6.1 148 0 n-Amyl Alcohol 15.9 5.9 13.9 108.6 0 Benzene 18.4 0 2 52.9 0 11.38507 Benzyl Alcohol 18.4 6.3 13.7 103.8 0 Benzyl Benzoate 20 5.1 5.2 190.3 0 1-Butanol 16 5.7 15.8 92 0 2-Butanol 15.8 5.7 14.5 92 0 n-Butyl Acetate 15.8 3.7 6.3 132.6 0 t-Butyl Acetate 15 3.7 6 134.8 0 t-Butyl Alcohol 15.2 5.1 14.7 96 0 Butyl Benzoate 18.3 5.6 5.5 178.1 0 Butyl Diglycol Acetate 16 4.1 8.2 208.2 0 Butyl Glycol Acetate 15.3 7.5 6.8 171.2 0 n-Butyl Propionate 15.7 5.5 5.9 149.3 0 Caprolactone (Epsilon) 19.7 15 7.4 110.8 0 Chloroform 17.8 3.1 5.7 80.5 1 7.075453 m-Cresol 18.5 6.5 13.7 105 1 6.563973 Cyclohexane 16.8 0 0.2 108.9 0 12.82752 Cyclohexanol 17.4 4.1 13.5 105.7 0 Cyclohexanone 17.8 8.4 5.1 104.2 0 Di-isoButyl Ketone 16 3.7 4.1 177.4 0 Diacetone Alcohol 15.8 8.2 10.8 124.3 0 Diethyl Ether 14.5 2.9 4.6 104.7 0 10.87429 Diethylene Glycol Monobut 16 7 10.6 170.4 0 Dimethyl Cyclohexane 16.1 0 1.1 140 0 Dimethyl Sulfoxide (DMSO) 18.4 16.4 10.2 71.3 1 7.066692 1,4-Dioxane 17.5 1.8 9 85.7 0 8.160898 1,3-Dioxolane -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0 -
D1cp02001c1.Pdf
Electronic Supplementary Material (ESI) for Physical Chemistry Chemical Physics. This journal is © the Owner Societies 2021 Supplementary Material to Systematic optimization of a fragment-based force field against experimental pure-liquid properties considering large compound families: Application to oxygen and nitrogen compounds. Marina P. Oliveira and Philippe H. H¨unenberger 1 S.1 Compounds in the Calibration and Validation Sets The structures of the compounds included in the calibration and validation sets are illustrated in Figs. S.1 and S.2, respectively. cal Figure S.1: Structures of the Niso = 339 molecules with 1-6 carbon atom included in the calibration set. See Tab. S.1 for the corresponding names and CAS registry numbers. 2 3 4 5 val Figure S.2: Structures of the Niso = 836 molecules with 7-10 carbon atoms included in the validation set. See Tab. S.1 for the corresponding names and CAS registry numbers. 6 7 8 9 10 11 12 13 14 S.2 Reference Experimental Data sim The reference experimental data used in this work is reported in Tab. S.1. The Niso = 1175 molecules considered are referred to by their code, IUPAC name, CAS registry number, and whether they belong to the calibration (C) or validation (V) set. The structures of the com- pounds in these two sets are displayed in Figs. S.1 and S.2, respectively. For these molecules, tot simulations are performed at Nsim = 1405 thermodynamic state points, with indicated pressure P and temperature T . Simulations of the same compound performed at different P; T -points are distinguished by an extra letter (a, b or c) appended to the molecule code. -
Stembook 2018.Pdf
The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. -
I (Acts Whose Publication Is Obligatory) COMMISSION
13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods. -
N-Propyl Propionate Propyl Propanoate Propanoic Acid, Propyl Ester
Technical Data Sheet UCAR n-Propyl Propionate Propyl Propanoate Propanoic Acid, Propyl Ester CH3CH2COOCH2CH2CH3 Description Physical properties UCAR™ n-propyl propionate is a fast evaporating solvent. Its linear Molecular Weight 116.16 structure contributes to effective Relative Evaporation Rate nBuAc=1 1.2 viscosity reduction and improves solvent diffusion from coating films. Vapor Pressure at 20C, mmHg 10.7 Density at 20C lb/gal 7.34 Specific Gravity at 20/20C 0.881 Viscosity at 20C cP 0.7 Surface Tension (dynes/cm at 20C) 24.7 (dynes/cm at 25C) - Hansen Solubility Parameters, [cal/cm3]1/2 Total 8.6 Non-Polar 7.6 Polar 1.8 Hydrogen Bonding 3.6 Boiling Point, C at 760mm Hg 122.4 Solubility at 20C %Wt In Water 0.5 %Wt Water in Closed Cup Flash Point F 75 SARA 313 (see note 1†) N Hazardous Air Pollutant (see note 2††) N Electrical Resistivity MΩ >1000 † Note 1: Superfund Amendments and Reauthorization Act of 1986 (SARA) Title III Section 313 †† Note 2: Hazardous Air Pollutants listed under Title III of the Clean Air Act Classification/Registry Numbers CAS Number 106-36-5 (Please see second page) EINECS 203-389-7 *Trademark of The Dow Chemical Company UCAR™ n-Propyl Propionate Propyl Propanoate Propionic Acid, Propyl Ester Features Non-HAP (Hazardous Air Pollutant) Solvent Stronger solvency than acetate esters in high solids coatings Proper volatility for high solids coatings and printing inks applications Linear structure giving faster diffusion through coating and ink films High electrical resistivity for electrostatically sprayed -
T |?: 9. 3:08: Such Pharmaceutical Compositions. (52) U.S
USOO93O8213B2 (12) United States Patent (10) Patent No.: US 9,308,213 B2 Bannister et al. 45) Date of Patent: *Apr. 12,9 2016 (54) SOLID SOLUTION COMPOSITIONS AND USE (2013.01); A61 K9/2013 (2013.01); A61 K IN CHRONIC INFLAMMATION 31/192 (2013.01); A61 K3I/60 (2013.01); A61K 47/44 (2013.01); A61 K3 1/201 (2013.01); (71) Applicant: Infirst Healthcare Limited, London A61 K 3 1/202 (2013.01); A61K 31/25 (2013.01); (GB) A61 K 3 1/337 (2013.01); A61 K3I/704 (72) Inventors: Robin M. Bannister, Essex (GB); John (2013.01) Brew, Hertfordshire (GB); Richard R. (58) Field of Classification Search Caparros Wanderley, Buckinghamshire A61 K31/704; A61 K31/60; A61 K31/202 (GB) USPC .......................................... 514/159,570,571 See application file for complete search history. (73) Assignee: Infirst Healthcare Limited (GB) (*) Notice: Subject to any disclaimer, the term of this (56) References Cited patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days U.S. PATENT DOCUMENTS This patent is Subject to a terminal dis- 3,228,831 A 1/1966 Nicholson et al. claimer 3,800,038 A 3, 1974 Rudel 4,571.400 A 2f1986 Arnold 4,684.666 A 8, 1987 HaaS (21) Appl. No.: 14/155,108 4,918, 103 A 4/1990 Park et al. 5,011,852 A 4, 1991 Park et al. (22) Filed: Jan. 14, 2014 5,059,626 A 10, 1991 Park et al. 5,154,930 A 10/1992 Popescu (65) Prior Publication Data 5,552,160 A 9/1996 Liversidge et al. -
(12) United States Patent (10) Patent No.: US 8,772,273 B2 Makra (45) Date of Patent: Jul
US008772273B2 (12) United States Patent (10) Patent No.: US 8,772,273 B2 Makra (45) Date of Patent: Jul. 8, 2014 (54) FORMULATIONS AND USES OF RETINOIC (56) References Cited ACID RECEPTOR SELECTIVE AGONSTS U.S. PATENT DOCUMENTS (75) Inventor: Ferenc Makra, Palo Alto, CA (US) 5,556,844 A ck 9, 1996 Reichert et al. 514,171 2005/0113447 A1* 5/2005 Belloni et al. ................ 514,469 (73) Assignee: Quretino Therapeutics, Inc., Palo Alto, 2006/0280715 A1* 12/2006 Vishnupad et al. ........ 424.70.13 CA (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 W W 23's A. 3.1% U.S.C. 154(b) by 14 days. WO WOO 109076 A2 2/2001 WO WO 03062230 A1 T 2003 (21)21) Appl. NoNo.: 13/253,0149 OTHER PUBLICATIONS (22) Filed: Oct. 4, 2011 Jain, S., Journal of Dermatological Treatment (2004) 15, pp. 200 207.* (65) Prior Publication Data International Search Report and Written Opinion for PCT/US2012/ US 2013/0085166 A1 Apr. 4, 2013 058726, issued May 7, 2013. * cited by examiner (51) Int. Cl. AOIN 43/00 (2006.01) Primary Examiner — Scott Long A6 IK3I/9 (2006.01) Assistant Examiner — Lyndsey Beckhardt A6 IK3I/35 (2006.01) (74) Attorney, Agent, or Firm — Morgan, Lewis & Bockius A6 IK3I/21 (2006.01) LLP A6 IK 9/14 (2006.01) (52) U.S. Cl. (57) ABSTRACT USPC ........... 514/183; 514/569; 514/456; 514/510; The invention provides retinoic acid receptor (RAR) selective 424/484 agonists and formulations thereof for the treatment of disease (58) Field of Classification Search or for inducing a medically beneficial effect. -
Propyl Propionate Safety Data Sheet According to Federal Register / Vol
Propyl propionate Safety Data Sheet according to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations Date of issue: 05/26/2015 Version: 1.0 SECTION 1: Identification 1.1. Identification Product form : Substance Substance name : Propyl propionate CAS-No. : 106-36-5 Product code : (US) W1740 Formula : C6H12O2 Synonyms : Propanoate, propyl / Propanoic acid, propyl ester / Propionic acid, propyl ester / Propyl propanoate / n-Propyl propionate / n-Propyl propanoate 1.2. Recommended use and restrictions on use No additional information available 1.3. S upplie r Synerzine 5340 Hwy 42 S Ellenwood, Georgia 30294 - USA T 404-524-6744 - F 404-577-1651 [email protected] - www.synerzine.com 1.4. Emergency telephone number Emergency number : Infotrac 1-800-535-5053 (Contract# 102471) Dial +1-352-323-3500 when outside the US SECTION 2: Hazard(s) identification 2.1. Classification of the substance or mi xt ure GHS -US classification Flammable liquids Category H225 Highly flammable liquid and vapour 2 Acute toxicity H332 Harmful if inhaled (inhalation:dust,mist) Category 4 Skin corrosion/irritation H315 Causes skin irritation Category 2 Serious eye damage/eye H319 Causes serious eye irritation irritation Category 2A Full text of H statements : see section 16 2.2. GHS Label elements, including precautionary statemen ts GHS-US labeling Hazard pictograms (GHS-US) : Signal word (GHS-US) : Danger Hazard statements (GHS-US) : H225 - Highly flammable liquid and vapour H315 - Causes skin irritation H319 - Causes serious eye irritation H332 - Harmful if inhaled Precautionary statements (GHS-US) : P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources.